An estradiol-Porphyrin conjugate selectively localizes into estrogen receptor-Positive breast cancer cells

Swamy, Narasimha; James, David A.; Mohr, Scott C.; Hanson, Robert N.; Ray, Rahul

doi:10.1016/s0968-0896(02)00242-0

Cited by 52 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several approaches have been investigated to increase the specificity of photosensitisers for cancerous tissues (Brasseur et al, 1999;Gijsens et al, 2000;Swamy et al, 2002). Of considerable interest has been the conjugation of photosensitisers to monoclonal antibodies (MAb) directed against tumour-associated antigens; this approach is often termed photoimmunotherapy (PIT).…”

mentioning

confidence: 99%

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

et al. 2005

View full text Add to dashboard Cite

A promising approach to increase the specificity of photosensitisers used in photodynamic therapy has been through conjugation to monoclonal antibodies (MAb) directed against tumour-associated antigens. Many of the conjugations performed to date have relied on the activated ester method, which can lead to impure conjugate preparations and antibody crosslinking. Here, we report the development of photosensitiser -MAb conjugates utilising two porphyrin isothiocyanates. The presence of a single reactive isothiocyanate allowed facile conjugation to MAb FSP 77 and 17.1A directed against internalising antigens, and MAb 35A7 that binds to a non-internalising antigen. The photosensitiser -MAb conjugates substituted with 1 -3 mol of photosensitiser were characterised in vitro. No appreciable loss of immunoreactivity was observed and binding specificity was comparable to that of the unconjugated MAb. Substitution with photosensitiser had a minimal effect on antibody biodistribution in vivo for the majority of the conjugates, although a decreased serum half-life was observed using a cationic photosensitiser at the higher loading ratios. Tumour-to-normal tissue ratios as high as 33.5 were observed using MAb 35A7 conjugates. The internalising conjugate showed a higher level of phototoxicity as compared with the non-internalising reagent, using a cell line engineered to express both target antigens. These data demonstrate the applicability of the isothiocyanate group for the development of high-quality conjugates, and the use of internalising MAb to significantly increase the photodynamic efficiency of conjugates during photoimmunotherapy.

show abstract

mentioning

confidence: 99%

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…As these receptors represent a potential site for directing receptor-mediated cellular uptake, photodynamic researchers utilized them as vehicles to selectively deliver photosensitizing agents. Thus, the overexpression of receptors in breast cancer was harnessed synergistically with the tumor-migrating effect of several PSs to selectively deliver target molecule-PS conjugates into breast tumor cells, and preferentially kill the tumor cells upon exposure to red light [19][20][21][22][23][24][25][26][27][28][29][30][31][32] (Table 1). Developments in these specific types of receptor-targeting approaches highlight their potential advantages in the discovery of more effective cancer photochemotherapy agents.…”

Section: Pdt and Breast Cancer Receptor-targeted Agentsmentioning

confidence: 99%

“…High-affinity conjugate protein binding James et al [19] Estradiol receptor Tetraphenylporphyrin High-affinity conjugate cell binding Swamy et al [20] Estradiol receptor Pyropheophorbide a Conjugate-selective cell death Fernandez Gacio et al [21] Estradiol receptor Pyropheophorbide a Conjugate-selective cell death El-Akra et al [22] Estradiol receptor Pyropheophorbide a High conjugate internalization Sadler et al [23] Estradiol receptor Chlorin e6-dimethyl ester Conjugate-selective cell death Swamy et al [24] Human epidermal growth factor receptor Verteporfin and pyropheophorbide a Conjugate-selective but less phototoxic Savellano et al [25] Human epidermal growth factor receptor Verteporfin and pyropheophorbide a Conjugate-selective cell death Bhatti et al [26] Human epidermal growth factor receptor Zinc phthalocyanine (plus nanoparticules) Conjugate-selective cell death Stuchinskaya et al [27] Human epidermal growth factor receptor Sn-(IV) chlorin e6 monoethylenediamine Conjugate-selective cell death Gijsens et al [32] Tisular factor (factor VII receptor) Verteporfin Conjugate-selective cell death Hu et al [28] Tisular factor (factor VII receptor) Chlorin e6 Conjugate-selective cell death Duanmu et al [29] Gonadotropin-releasing hormone receptor Zinc phthalocyanine Conjugate-selective cell death Xu et al [30] Gonadotropin-releasing hormone receptor Protoporphyrin IX Conjugate-selective cell death Rahimipour et al [31] Lamberti MJ et al . Photodynamic therapy on breast cancer…”

Section: Estradiol Receptor Tetraphenylporphyrinmentioning

confidence: 99%

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity

Lamberti

Vittar

Rivarola

2014

WJCO

View full text Add to dashboard Cite

Photodynamic therapy is a minimally invasive and clinically approved procedure for eliminating selected malignant cells with specific light activation of a photosensitizer agent. Whereas interstitial and intra-operative approaches have been investigated for the ablation of a broad range of superficial or bulky solid tumors such as breast cancer, the majority of approved photodynamic therapy protocols are for the treatment of superficial lesions of skin and luminal organs. This review article will discuss recent progress in research focused mainly on assessing the efficacies of various photosensitizers used in photodynamic therapy, as well as the combinatory strategies of various therapeutic modalities for improving treatments of parenchymal and/or stromal tissues of breast cancer solid tumors. Cytotoxic agents are used in cancer treatments for their effect on rapidly proliferating cancer cells. However, such therapeutics often lack specificity, which can lead to toxicity and undesirable side effects. Many approaches are designed to target tumors. Selective therapies can be established by focusing on distinctive intracellular (receptors, apoptotic pathways, multidrug resistance system, nitric oxidemediated stress) and environmental (glucose, pH) differences between tumor and healthy tissue. A rational design of effective combination regimens for breast cancer treatment involves a better understanding of the mechanisms and molecular interactions of cytotoxic agents that underlie drug resistance and sensitivity. Key words: Photodynamic therapy; Breast cancer; Tumor microenvironment; Treatment combination; Synergism Core tip: Breast cancer is the most common cancer in women worldwide. However, effective therapies that reduce the high mortality rate and improve patient quality of life are still unavailable. In recent years, the use of photodynamic therapy has been examined for use in breast cancer treatment. Photodynamic therapy provides a new and promising antitumor strategy that could be implemented, alone or in combination with other approved or experimental therapeutic approaches, to a wide range of applications.

show abstract

“…They are used as photosensitizers for photodynamic therapy [3], in saccharide sensing [4][5][6][7][8][9], and anion binding [10]. Nearly all studies have been limited so far to bileacid based structures [11][12][13][14], with a few exceptions of porphyrin conjugates of estrogens [15][16][17], androgens [18,19] and cholesterol [20].…”

Section: Introductionmentioning

confidence: 99%

Design and studies of novel polyoxysterol-based porphyrin conjugates

et al. 2012

View full text Add to dashboard Cite

a b s t r a c tNew types of steroid-porphyrin conjugates derived from 20-hydroxyecdysone (20E) and 24-epibrassinolide (EBl) were synthesized. An exceptional regioselectivity in the reaction of both steroids with porphyrin boronic acids was found to give side-chain-conjugated boronic esters as sole products. UV-Vis-, fluorescence and NMR spectroscopy yielded similar data for all the studied compounds confirming the solvent driven supramolecular assembly with formation of J-aggregates. CD measurements of water diluted solutions showed a clear difference between 20E and EBl conjugates. The latter showed a strong supramolecular chirality, whereas 20E J-aggregates did not.

show abstract

An estradiol-Porphyrin conjugate selectively localizes into estrogen receptor-Positive breast cancer cells

Cited by 52 publications

References 13 publications

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity

Design and studies of novel polyoxysterol-based porphyrin conjugates

Contact Info

Product

Resources

About